BRCA1 and cancer: Molecular alterations affecting the DDR genes, such as ERCC1/2 and BRCA1/2, are emerging as predictors of cancer response to conventional chemo-therapeutics, and their evaluation is now proposed in several clinical trials including the NSCLC with the aim to correlate the defects of selected DDR genes with the efficacy of new targeted therapies [11,51,52,53,54,55,56,57,58,59,60].